Article Text

Parsonage-Turner syndrome following COVID-19 vaccination
  1. Young Gi Min1,2,
  2. Jee-Eun Kim3,
  3. Ji Young Hwang4,
  4. Je-Young Shin1,
  5. Jung-Joon Sung1,2,
  6. Yoon-Ho Hong5
  1. 1 Neurology, Seoul National University Hospital, Seoul, South Korea
  2. 2 Translational Medicine, Seoul National University College of Medicine, Seoul, South Korea
  3. 3 Neurology, College of Medicine, Ewha Womans University, Seoul, South Korea
  4. 4 Radiology, College of Medicine, Ewha Womans University, Seoul, South Korea
  5. 5 Neurology, Neuroscience Research Institute, Medical Research Council, Seoul National University College of Medicine, Seoul Metropolitan Government Boramae Medical Center, Seoul, South Korea
  1. Correspondence to Professor Yoon-Ho Hong, Neurology, Neuroscience Research Institute, Medical Research Council, Seoul National University College of Medicine, Seoul Metropolitan Government Boramae Medical Center, Seoul 07061, South Korea; nrhong{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


Parsonage-Turner syndrome (PTS), also known as neuralgic amyotrophy, is an acute idiopathic brachial neuritis, typically characterised by acute onset of excruciating pain followed by weakness and wasting in the upper limb.1 Antecedent events such as infection, exercise, trauma, surgery and vaccination are reported in approximately 50% of affected individuals.1 PTS has been reported following COVID-19 vaccination, but the current literature is limited to several case reports and a passive reporting system.2 3 Herein, we report on the clinical, radiological and laboratory features of 12 cases with PTS post COVID-19 vaccination.


We reviewed medical records of the patients who were diagnosed with PTS following COVID-19 vaccination in three referral hospitals (Seoul, South Korea) between June and October 2021. We collected and analysed the detailed clinical information as follows: the type and order (in case of different types) of COVID-19 vaccine, laterality of symptom presentation, timeline regarding the vaccination, symptom onset and nadir, clinical presentation, motor grade at nadir, the results of electrodiagnosis, brachial plexus MRI, cerebrospinal fluid (CSF) analysis, treatment regimen and the outcomes.


We identified 12 patients (7 men and 5 women) who developed PTS after a receipt of COVID-19 vaccine. Clinical features of the patients are summarised in table 1 (and online supplemental figure). Age ranged between 23 and 81 (average 51). Vaccination was the only possible trigger in all cases. Six patients had received adenoviral vector-based vaccines (four received AstraZeneca and two received Janssen), and the others had mRNA-based vaccines (five had Pfizer and one had Moderna). All but two developed PTS after receipt of the first dose of COVID-19 vaccine. The interval from the vaccination to symptom onset and nadir ranged between 2 days and 16 days (median 6.5) and between 5 days and 55 days (median 20.5), respectively. Disease severity at nadir varied across patients, with Medical Research Council grade of the weakest muscles ranging from 2 to 5. Electrodiagnostic studies revealed abnormalities consistent with brachial neuritis in most patients.

Supplemental material

Table 1

Summary of clinical characteristics

Intriguingly, PTS occurred at the same side of vaccine injection in all but two cases (contralateral in patient 8 and bilateral in patient 12). Notably, MRI or sonographic evaluations revealed prominent ipsilateral axillary and/or cervical lymph nodes in seven of eight patients (87.5%) (online supplemental figure). CSF analysis showed albuminocytological dissociation in all three tested patients (patients 1, 3 and 12). We administered oral or intravenous corticosteroid in all patients but three: two patients showed rapid clinical improvement (patients 5 and 7), and one patient refused to receive the treatment (patient 4). We noted a variable degree of recovery at the last follow-up: complete in three, partial in four and poor in five.


Vaccination is one of the known potential triggers of PTS, with case series and reports for tetanus, smallpox, human papillomavirus, influenza and, recently, COVID-19 vaccines.2 To date, there have been seven publications reporting 10 cases of PTS following COVID-19 vaccination (online supplemental table). While most of the reported cases (8/10) received mRNA vaccines, our observations implicate the adenoviral vector-based vaccine as well in 6 of 12 cases. The time interval between vaccination and PTS onset ranged from 2 to 16 days, which is in line with previous reports and coincided with the expected time course of the immune response against COVID-19 vaccines. Similar to previous reports, we found that PTS post COVID-19 vaccination mostly takes the classic form, but also observed atypical phenotypes of pure sensory or painless motor-predominant form in two cases.4

Intriguingly, we found that PTS occurred on the same side of vaccination in all except two cases. Combined with all previously reported cases, the rate of ipsilateral PTS reaches 77.3% (17 of 22 cases). Meanwhile, we noted an unexpectedly high frequency of ipsilateral reactive lymphadenopathy in our cases (87.5%). Although it has not been addressed in the context of PTS, reactive lymphadenopathy is reportedly a frequent finding at imaging with an incidence of up to 53% with the COVID-19 mRNA vaccines in patients with breast cancer.5 Taken together, we proposed the need for further research to investigate whether these local immune reactions are involved in the pathogenesis of ipsilateral brachial neuritis or whether they are simply observed together by chance.2 4

It should be emphasised that we cannot establish a robust causal relationship between PTS and COVID-19 vaccination with case series. It is also worth mentioning that the benefits of COVID-19 vaccination far outweigh the potential risks. Corroborating the findings of previous case reports, our observations suggest that COVID-19 vaccines may be associated with PTS characterised by ipsilateral occurrence and possibly accompanied by reactive lymphadenopathy. Further studies are warranted to assess the causality and significance of the ipsilateral association.

Ethics statements

Patient consent for publication

Ethics approval

This study involves human participants and was approved by the institutional review boards (IRBs) of Seoul National University Hospital (IRB 2110-049-1261), Seoul Metropolitan Government Boramae Medical Center (IRB 30-2021-122) and Ewha Womans University Seoul Hospital (IRB 2021-09-021). The participants gave informed consent to participate in the study before taking part.


Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.


  • YGM and J-EK are joint first authors.

  • Twitter @Yoonho

  • YGM and J-EK contributed equally.

  • Contributors YGM, J-EK and Y-HH conceptualised, designed the study and wrote the manuscript. YGM, JYH and J-EK collected data. YGM and J-EK prepared the figure. J-YS and J-JS interpreted the data. Y-HH supervised the work.

  • Funding This work was supported by a focused clinical research grant-in-aid (03-2016-0300) from the Seoul National University Hospital Research Fund.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.